

## ***Annual Report 2024***

### **Introduction**

There were no changes to the Trustee and executive boards of GAFFI during 2024 as the boards sought to implement the strategy and plans developed during 2023 and 2024 and to build on the excellent work since GAFFI's inception and enhance its impact. The Trustee board consists of Oddi Aasheim, David Allmond, Dr. Nkechi Azie, Yasuaki Mori, Skhumbuzo Ngozwana, Professor David Perlin and Professor Juan Luis Rodriguez Tudela. The executive board consists of Oddi Aasheim (Chair and Chief Strategy Officer), Juan Luis Rodríguez Tudela (Interim CEO, Director for Latin America Programmes), Emma Orefuwa (Director for African Programmes) and Timothy Moss (Head of Finance and Governance). The boards reflect the international work of GAFFI. GAFFI and GAFFI UK have identical Board membership to facilitate achieving GAFFI's goals.

### **Aims**

- **GAFFI's strategy** focuses on enhancing outcomes by prioritising timely diagnosis and ensuring access to treatment for Fungal Disease in immunocompromised patients residing in low-to-middle-income countries (LMICs);
- **GAFFI presents a well-established model** which empowers healthcare professionals responsible for managing HIV in LMICs, enhancing outcomes in opportunistic fungal infections among people who live with HIV;
- **GAFFI actively cultivates and empowers regional and local hubs and networks**, enabling them to enhance access to cost-effective and efficient diagnostics including detection of antifungal resistance and treatments.

# Global Action For Fungal Infections

[www.gaffi.org](http://www.gaffi.org)



## Donors and supporters

We would again like to thank all those who continue to support GAFFI with generous donations, donations in kind (including office space), and our country Ambassadors. Fuller details of our supports and Ambassadors are available on our website.

## Strategy and Plans

GAFFI is implementing the transformational strategy developed during 2023 and 2024 to elevate GAFFI's impact. The Board strategic focus on reducing mortality through access to diagnosis and treatment for Fungal Disease by providing the needed tools and expertise hubs to diagnose the Fungal Diseases that affect the patient, including detection of antifungal resistance includes the implementation of Fungal Disease Response Centers as soon as practically possible, building on the successful Latin America model.

GAFFI's achievements in 2024 include:

1. An intervention project in collaboration with the Mycology Branch of the US Centre for Diseases Control (CDC) entitled: "Scaling up Access to Diagnosis for Fungal Disease Following Successful Proof of Concept in Guatemala".
2. An intervention project in collaboration with JYLAG entitled: "A Diagnostic Laboratory Hub for global access to diagnoses of Fungal Disease in Santa Fe province, Argentina".
3. Partnering with Africa CDC in establishing hubs and formal expertise and ambassador networks in fungal disease across Africa.
4. Building on the learning and insights gained from the Latin America programmes, for similar activities in Africa.

# Global Action For Fungal Infections

[www.gaffi.org](http://www.gaffi.org)



5. Developing clinical forms that can be used globally for training and validating of algorithms for Fungal disease.
6. Working with the WHO for establishing the Blueprint for Fungal Disease.
7. Establishing with PAHO, CDC, CMM University of Exeter, CMM LATAM and Instituto de Salud Carlos the Fungal Interest group for the Americas
8. Develop partnerships for GAFFI that will include fungal disease as an additional aspect to planned projects, notably in the context of AMR programmes, but also others.

Oddi Aasheim  
President/président  
25/03/2025